Study of the Efficacy and Safety of MEDI4893



Status:Completed
Conditions:Pneumonia
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:12/19/2018
Start Date:October 10, 2014
End Date:October 2, 2018

Use our guide to learn which trials are right for you!

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects.

Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused
by Staphylococcus aureus in high-risk patients


Inclusion Criteria:

- Colonized with Staphylococcus aureus, expected to require prolonged intubation and
mechanical ventilation, without any evidence of active pneumonia.

Exclusion Criteria:

- Staphylococcal disease at randomisation; lung injury score consistent with pneumonia;
current lung disease; chronic tracheostomy patients; currently receiving systemic
anti-staphylococcal antibiotics; moribund patients.
We found this trial at
3
sites
?
mi
from
Arlon,
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials